Biomerica Inc (NASDAQ:BMRA) does about 7.80M shares in volume on a normal day but saw 1526707 shares change hands in the recent trading day. The company now has a market cap of 11.02M USD. Its current market price is $0.60, marking a decrease of -0.15% compared to the previous close of $0.60. The 52 week high reached by this stock is $1.35 whilst the lowest price level in 52 weeks is $0.24.
Biomerica Inc (BMRA) has a 20-day trading average at $0.4170 and the current price is -55.48% off the 52-week high compared with 148.86% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3635 and its 200-day simple moving average is $0.4294. If we look at the stock’s price movements over the week, volatility stands at 21.48%, which decreases to 19.64% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 67.04 to suggest the stock is neutral.
The consensus objective for the share price is $13.00, suggesting that the stock has a potential upside of 95.38% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 10, 2020 when Colliers Securities initiated the stock to “Buy” and issued a price target of $13.
The current price level is 44.13%, 65.32%, and 39.98% away from its SMA20, SMA50, and SMA200 respectively, with the BMRA price moving below the 50-day SMA on current market day. Biomerica Inc (BMRA) stock is down -14.87% over the week and 115.49% over the past month. Its price is 100.27% year-to-date and -38.05% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 95.38 percent from here.
Outstanding shares total 18.34M with insiders holding 11.79% of the shares and institutional holders owning 12.36% of the company’s common stock. The company has a return on investment of -103.83% and return on equity of -77.33%. The beta has a value of -0.87. Price to book ratio is 2.15 and price to sales ratio is 1.97.
